Top Markets
#1 Doge Strategy Doge Strategy +953,314.18%
#2 Noon Noon +12,208.80%
#3 Siren Siren +112.06%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +46.63%
#6 Gigachad Gigachad +28.15%
#7 Ontology Ontology +20.38%
#8 Scor Scor +18.84%
#9 Win Win +17.98%
#10 TRIA TRIA +17.79%
Coin of the day
Doge Strategy Doge Strategy
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Kedudukan dalam Saham #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Harga Saham
$0.0416118
Modal Pasaran
$12.78M
Perubahan (1 hari)
1.72%
Perubahan (1 tahun)
-22.01%
Negara
AU
Perdagangan Noxopharm Limited (NOX)

Kategori

Healthcare
Pendapatan untuk Noxopharm Limited (NOX)
Pendapatan pada Dec 2025 TTM: $-4.82M
Menurut laporan kewangan terkini Noxopharm Limited, pendapatan semasa syarikat ialah $-4.82M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-3.99M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $-14.02M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Noxopharm Limited dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-4.82M 49.79%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -424,852.71%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -96,506.98%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -108,705.27%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -44,485.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -33,617.45%
AU